Next Article in Journal
Awareness and Use of the Rapid Palliative Radiotherapy Program by Family Physicians in Eastern Ontario: A Survey
Previous Article in Journal
Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 1

1
Department of Medicine, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
2
Center for Natural Healing, Ashland, OR, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2006, 13(1), 14-26; https://doi.org/10.3747/co.v13i1.77
Submission received: 1 November 2005 / Revised: 1 December 2005 / Accepted: 3 January 2006 / Published: 1 February 2006

Abstract

An integrative approach for managing a patient with cancer should target the multiple biochemical and physiologic pathways that support tumour development and minimize normal-tissue toxicity. Angiogenesis is a key process in the promotion of cancer. Many natural health products that inhibit angiogenesis also manifest other anticancer activities. The present article focuses on products that have a high degree of anti-angiogenic activity, but it also describes some of the many other actions of these agents that can inhibit tumour progression and reduce the risk of metastasis. Natural health products target molecular pathways other than angiogenesis, including epidermal growth factor receptor, the HER2/neu gene, the cyclooxygenase-2 enzyme, the nuclear factor kappa-B transcription factor, the protein kinases, the Bcl-2 protein, and coagulation pathways. The herbs that are traditionally used for anticancer treatment and that are anti-angiogenic through multiple interdependent processes (including effects on gene expression, signal processing, and enzyme activities) include Artemisia annua (Chinese wormwood), Viscum album (European mistletoe), Curcuma longa (curcumin), Scutellaria baicalensis (Chinese skullcap), resveratrol and proanthocyanidin (grape seed extract), Magnolia officinalis (Chinese magnolia tree), Camellia sinensis (green tea), Ginkgo biloba, quercetin, Poria cocos, Zingiber officinalis (ginger), Panax ginseng, Rabdosia rubescens hora (Rabdosia), and Chinese destagnation herbs. Quality assurance of appropriate extracts is essential prior to embarking upon clinical trials. More data are required on dose–response, appropriate combinations, and potential toxicities. Given the multiple effects of these agents, their future use for cancer therapy probably lies in synergistic combinations. During active cancer therapy, they should generally be evaluated in combination with chemotherapy and radiation. In this role, they act as modifiers of biologic response or as adaptogens, potentially enhancing the efficacy of the conventional therapies.
Keywords: angiogenesis; anti-angiogenic; natural health products; herbal medicine; anticancer; clinical trials; integrative; molecular biology angiogenesis; anti-angiogenic; natural health products; herbal medicine; anticancer; clinical trials; integrative; molecular biology

Share and Cite

MDPI and ACS Style

Sagar, S.M.; Yance, D.; Wong, R.K. Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 1. Curr. Oncol. 2006, 13, 14-26. https://doi.org/10.3747/co.v13i1.77

AMA Style

Sagar SM, Yance D, Wong RK. Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 1. Current Oncology. 2006; 13(1):14-26. https://doi.org/10.3747/co.v13i1.77

Chicago/Turabian Style

Sagar, S.M., D. Yance, and R.K. Wong. 2006. "Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 1" Current Oncology 13, no. 1: 14-26. https://doi.org/10.3747/co.v13i1.77

Article Metrics

Back to TopTop